The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1097
ISSUE1097
February 5, 2001
Argatroban For Treatment of Heparin-Induced Thrombocytopenia
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Argatroban For Treatment of Heparin-Induced Thrombocytopenia
February 5, 2001 (Issue: 1097)
Argatroban, a small-molecule synthetic derivative of L-arginine, is a direct thrombin inhibitor approved by the FDA for use as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.